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Introduction: Currently, over 200 million people across the globe suffer from impaired 
hearing, a large part o f  which is caused by ear damage, located in the auditory nerve or cochlea, 
which is defined by sensorineural hearing loss. The difficulty o f  identifying the mechanism o f  
occurrence o f  this disease makes it impossible to establish so far, an effective therapy, that would 
ensure certainly a satisfactory auricular recovery after administration. Thus, the therapeutic 
management o f  sensorineural hearing loss syndrome remains a very controversial topic, despite 
advances in technology, because o f  a multifactorial pathogenesis and the low recovery rate o f  
hearing. In Moldova this problem exists and has difficulties in some aspects o f  this pathology such 
as genetic diagnosis and early correction o f  genetic forms o f  deafness.
Purpose and objectives: Statistical evaluation o f  a group o f  patients diagnosed with 
sensorineural hearing loss, and literature analysis on groups o f  medications used in the treatment o f  
sensorineural hearing loss.
Materials and methods: Clinical-statistic study according to different criteria o f  classification.
Results: Our results show an almost equal distribution o f  cases o f  congenital sensorineural 
hearing loss between the sexes, with a slight predominance o f  males to the females (51.56% male to 
48.44% female). Study the distribution o f  cases by area o f  origin showed a higher proportion o f  patients 
in urban areas (59.36% urban versus 40.63% rural). Studying the age group o f the 28 cases we have 
found that the dominant age group between 11 and 20 to 34.44%. We found that the highest percentage 
o f patients is represented by those with profound sensorineural hearing loss-11 patients representing 
36.5% o f  all patients. Hearing loss treatment is a combination o f  remedies including vasodilators, 
nootropic and antioxidants. All these remedies used together contribute to improve hemodynamics in 
the region o f  the inner ear, increase metabolism and stimulate the auditory analyzer.
Conclusion: Congenital sensorineural hearing loss remains a very common disease that 
requires specific treatment behavior, especially combined.
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Introduction: About one-tenth o f  medicinal products present on the pharmaceutical market 
are fixed-dose combinations. Fixed-dose combination products are becoming a popular treatment 
option because o f  increased patient’s compliance and convenience, improved clinical effectiveness, 
reduced cost for the patient and reduced side effects. Due to this range o f  advantages, combined 
drugs can be used in otorhinolaryngology practice, especially in the pharmacotherapy o f  ear 
diseases, because o f  the severe consequences otitis media produces (such as deafness due to keloid 
scars o f  the tympanic membrane).
Materials and methods: For research, State Nomenclature o f  medicines from Republic o f  
Moldova was used (26.03.2014); patient information leaflets; quality standards o f  analytical 
documents and therapeutic protocols in otorhinolaryngology (section "ear diseases").
Results: There are 642 combined drugs including: 531 combined drugs, 75 phytotherapeutic 
combined drugs and 36 biological combined drugs registered in State Nomenclature o f  drugs from
239
